Opioid use, abuse, and associated deaths have skyrocketed in the United States over the past decade. Since 1999, the number of opioid-related deaths has quadrupled
Joanna Lewis, PharmD, MBA
Advertisement
Joanna Lewis graduated from MUSC in 2007. Since then, she has held a variety of pharmacy practice roles, most recently a leadership position in the Department of Pharmacy at Duke University Hospital. Some of her responsibilities included medication safety, quality improvement, oversight of the financial charge capture process, and coordinating the implementation of a new technology system. She is passionate about precepting and mentoring new practitioners, as well as making the practice of pharmacy better.
Articles by Joanna Lewis, PharmD, MBA
About 900,000 people are affected by VTE/ PE in the United States each year, and about 100,000 people die as a result, according to the CDC.
Diabetes is a complex, chronic disease requires a multifaceted approach to management that combines education and support, lifestyle modifications, and pharmacological treatment.
When available treatment guidelines for patients with cancer are followed, 70% to 90% can achieve adequate pain relief.
Biologics play a significant role in patient care, but because of the high cost of these medications, they may be inaccessible to patients and increase health care costs.
Colorectal cancer, also called colon cancer, is the second leading cause of cancer-related deaths in the United States of the cancers affecting both men and women.
Over the last few months, new developments have taken place within the biosimilar market including new drug approvals and guidance documents released by the FDA.
Oncology pharmacists play an important role in the delivery of care to patients living with cancer.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Blenrep Receives FDA Approval for Treatment of Relapsed or Refractory Multiple Myeloma
2
Two Doses of PCV20 in Lymphoma Survivors Elicits Greater Humoral Response
3
Elinzanetant Demonstrates Rapid and Sustained Efficacy in Reducing Vasomotor Symptoms Across OASIS Clinical Trials
4
Early Real-World Experience with VIMKUNYA Consistent with Clinical Trial Findings
5
